https://www.selleckchem.com/products/akti-1-2.html
The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months' trastuzumab, tested in registration trials, was adopted as standard adjuvant treatment in 2006. Subsequently, were demonstrated using 9 weeks of trastuzumab. Shorter durations were therefore tested for non-inferiority. To establish whether or not 6 months' adjuvant trastuzumab is non-inferior to 12 months' in the treatm
Like
Comment
Share
